IL2 and head and neck squamous cell carcinoma: We translated an activation protocol from a previous phase I/II trial (Clin-Gov-No-NCT01386619), which described stimulation of allogeneic NK cells (1000 IU/ml IL-2) with resultant increased distribution of NK cell subsets and high NCR expression levels (11), to NK cells isolated from our HNSCC patients.